FDA Issues FY2021 Report on the State of Pharmaceutical Quality

This report contains outcomes of OPQ's quality surveillance efforts and selected indicators and trends that provide insights into drug and m

Receive this email as a forward? Subscribe to CDER SBIA industry updates. FDA | CDER | Small Business and Industry Assistance INDUSTRY NEWS . FDA Issues FY2021 Report on the State of Pharmaceutical Quality   The Office of Pharmaceutical Quality (OPQ) within FDA's Center for Drug Evaluation and Research has published the fiscal year 2021 Report on the State of Pharmaceutical Quality which summarizes various measures of the pharmaceutical industry's ability to deliver quality drugs to U.S. patients and consumers. This report contains outcomes of OPQ's quality surveillance efforts and selected indicators and trends that provide insights into drug and manufacturing site quality. FDA uses the State of Pharmaceutical Quality to inform research, regulatory decision-making, and surveillance activities across more than 4,000 manufacturing sites and more than 150,000 drug products. OPQ shares the information in this report so external stakeholders can better understand the quality of the U.S. drug supply. Together, FDA and our stakeholders can strengthen the quality of drugs in the U.S. market and the reliability of global drug manufacturing. Please read OPQ's Report on the State of Pharmaceutical Quality and join us in a commitment to quality.   The Small Business and Industry Assistance (SBIA) program in the Center for Drug Evaluation and Research  provides guidance, education and updates for regulated industry. Subscribe to CDER SBIA Email Updates Register for Upcoming Training View 2021 Recordings on YouTube Follow on LinkedIn Follow on Twitter This is an automated message delivery system. Replying to this message will not reach the CDER SBIA staff. If you have comments or questions, contact us at CDERSBIA@fda.hhs.gov or 1-866-405-5367 or (301) 796-6707.  SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA